CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02812420
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:17.623222+00:00
Published At: 2026-03-05T00:00:00+00:00
Record Updated At: 2026-03-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Hydronephrosis", "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant", "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant", "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant", "Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant", "Renal Pelvis Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage II Renal Pelvis Cancer AJCC v7", "Stage II Ureter Cancer AJCC v7", "Stage II Urethral Cancer AJCC v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Renal Pelvis Cancer AJCC v7", "Stage III Ureter Cancer AJCC v7", "Stage III Urethral Cancer AJCC v7", "Stage IV Renal Pelvis Cancer AJCC v7", "Stage IV Ureter Cancer AJCC v7", "Stage IV Urethral Cancer AJCC v7", "Ureter Urothelial Carcinoma", "Urethral Urothelial Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-05"
protocolSection.identificationModule.nctId: "NCT02812420"
protocolSection.identificationModule.officialTitle: "A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.